Complex | |
AACDB_ID: | 3123 |
PDBID: | 6WIR |
Chains: | AB_C |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.96 |
Reference: | 10.1371/journal.pone.0232311 |
Antibody | |
Antibody: | Secukinumab Fab |
Antibody mutation: | No |
INN (Clinical Trial): | Secukinumab(Approved) |
Antigen | |
Antigen: | Interleukin-17A |
Antigen mutation: | No |
Durg Target: | Q16552 |
Antibody
Heavy Chain: A
Mutation: NULL
>6WIR_A|Chain A|Fab heavy chain|Homo sapiens (9606) EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGHHHHHH |
Light Chain: B
Mutation: NULL
>6WIR_B|Chain B|Fab light chain|Homo sapiens (9606) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC |
Antigen
Chain: C
Mutation: NULL
>6WIR_C|Chain C|Interleukin-17A|Homo sapiens (9606) MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVAHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
A: TRP33 TRP47 SER56 GLU57 LYS58 TYR59 TYR60 GLY62 LYS65 TYR108 ILE109 HIS110 TRP112 B: SER30 SER31 TYR33 TYR92 GLY93 SER94 SER95 PRO96 C: LEU74 VAL83 TYR85 HIS86 MET87 ASN88 VAL90 VAL124 THR125 PRO126 ILE127 VAL128 HIS129 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)